<DOC>
	<DOCNO>NCT02209311</DOCNO>
	<brief_summary>Autologous MMSCs isolate oral mucosa biopsy sample expand vitro.Tissue engineer construction create use synthetic tricalcium phosphate autologous MMSCs . Patients undergo sinus lift procedure implantation create tissue-engineered construction . This single arm study control . All patient receive cell therapy .</brief_summary>
	<brief_title>Effectiveness Safety Method Maxilla Alveolar Process Reconstruction Using Synthetic Tricalcium Phosphate Autologous MMSCs</brief_title>
	<detailed_description>Patients verify diagnosis partially edentulous maxilla alveolar bone atrophy undergo oral mucosa biopsy autologous MMSCs derive expanded vitro 3-4 week . After tissue engineer construction create use synthetic tricalcium phosphate autologous MMSCs . Patients undergo sinus lift procedure implantation create tissue-engineered construction . Six month later patient undergo dental implant installation . Biopsy bone tissue site sinus lift perform part dental implant installation subsequent histological analysis bone specimen .</detailed_description>
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Alveolar Bone Loss</mesh_term>
	<criteria>Partially edentulous maxilla Height bone tissue area reconstruction 1 5 mm accord result conebeam compute tomography Minimal height augmentation 8 mm Volume bone tissue deficiency alveolar process maxilla 3 5 cm3 Implant installation schedule least 6 month sinuslift operation Patient familiar Participant information sheet Patient sign informed consent form Noninclusion Criteria : Chronic acute ear , nose throat disease , include maxillary sinusitis , foreign body maxillary sinus , odontogenic odontogenic maxillary sinus cyst Medical history surgery maxillary sinus precede 6 month prior implantation tissue engineer construction Progressive somatic disease ( clinically significant disease cardiovascular , hematopoietic endocrine system , systemic disease , immunopathological state ) Patients malignant tumor include postoperative period , patient receive chemotherapy and/or radiotherapy Any condition limit compliance ( dementia , neuropsychiatric disease , drug alcohol abuse etc . ) Significant weight loss ( &gt; 10 % body weight previous year ) unknown etiology Patient prescribe medication proven effect bone metabolism Diabetes mellitus , disorder thyroid parathyroid gland Clinically significant abnormality result laboratory test Participation clinical trial ( administration investigational drug ) 3 month prior inclusion Patient 's refusal participation trial Patient 's refusal compliance requirement contraception participation research Plaque index ( PI ) &gt; 15 % Sulcus bleeding index ( SBI ) &gt; 10 % Chronic kidney disease IV V stage ( creatinine clearance &lt; 30 mL/min estimate CockroftGault formula ) Confirmed syphilis , HIV , hepatitis B C infection Dropout Criteria : Perforation Schneider 's membrane 5 mm stage sinuslift operation Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Alveolar Bone Loss</keyword>
	<keyword>Alveolar Bone Atrophy</keyword>
	<keyword>Dental Implantation</keyword>
	<keyword>Bone Tissue Reconstruction</keyword>
	<keyword>Sinus Lift</keyword>
	<keyword>Autologous Multipotent Mesenchymal Stem Cell</keyword>
	<keyword>Autologous MMSCs</keyword>
	<keyword>Synthetic Tricalcium Phosphate</keyword>
	<keyword>Tissue Engineered Construction</keyword>
	<keyword>Oral Mucosa</keyword>
</DOC>